Breast Cancer Clinical Trial
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Summary
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Metastatic Triple-negative Breast Cancer
Willingness to undergo tumor biopsy
Patients must have received at least 1 prior chemotherapy regimen for metastatic disease
Exclusion Criteria:
Previous treatment with mTOR inhibitor
Untreated brain metastases
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There is 1 Location for this study
See Locations Near You
IU Simon Cancer Center
Indianapolis Indiana, 46202, United States
Indianapolis Indiana, 46202, United States
How clear is this clinincal trial information?